Kay Dickerson, an epidemiologist at Johns Hopkins University, has a new study in the New England Journal of Medicine comparing the outcomes of a dozen studies of Neurontin (gabapentin) to their original protocols. It turns out the researchers working on the Pfizer/Parke-Davis anticonvulsant drug changed the endpoints in eight of those trials while they were underway, she reports. MedPage Today has a good recap of her study here.


Comments
Thanks Merrill I've been
Thanks Merrill